Euthymics.com Website Review

ETHISMOS is the process from ancient Greece where habits that form good character were taught early in life. Our team develops medications for substance use disorders to achieve a change in habits, to support those returning to a life free of substance use We are developing a novel smoking cessation medication with potentially higher efficacy than standard medications. We hope to show reduced withdrawal effects, less impulsive smoking in response to behavioral cues, and less weight gain resulting in the possibility of We have years of development experience with the serotonin-preferring  triple reuptake inhibitor amitifadine and research-stage NE-preferring triple for ADHD. In March, 2017 Otsuka acquired Neurovance for $250m in up-front and near-term development > 1 billion smokers worldwide: 300m in China, 170M IN EUROPE, 100M IN INDIA: 50M IN US, 25M IN JAPAN, 23M IN BRAZIL. In many territories, a substantial number of smokers (up to half or more of smokers) attempt to quit each year, however in the US, only 7% According to the ITC Project China, 29% of smokers in China light up within 5 minutes of waking indicating a level of nicotine dependence higher than in any other territory. Patients attempting to quit with higher levels of dependence may find it more difficult and be more Millions of smokers across the globe have made the decision to use medications to help them quit Current medications address the craving. At ETHISMOS we are developing a treatment that addresses the negative mood that most frequently leads to relapse as well as weight gain Approximately 50 million US ad*lts smoke cigarettes daily; 55% of American smokers attempt to quit annually; 34% of those attempting to Approximately 318 million Chinese ad*lts smoke cigarettes daily; 22% of Chinese smokers attempt to quit annually; 11% of those attempting Approximately 170 million European ad*lts smoke cigarettes daily; 52% of Europeans attempt to quit annually; 11% of European smokers making